Event Type
Disclosure
Voluntary
Variant
8-K
of Form 8-K, including the accompanying Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
. Other Events. The Company has also made available a slide presentation relating to topline data from its Phase 2 EMBRAZE clinical trial in obesity evaluatin
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by the Company on June 18, 2025, furnished hereto. 99.2 10